Tema Oncology (CANC) ETF Holdings & Analysis
ETFOther
What CANC does
The Tema Oncology ETF (CANC) is designed to strategically invest in companies well-positioned to capitalize on significant advancements within cancer-focused biotechnology and the broader healthcare sector.
Fund profile
Top holdings
| Holding | Weight | |
|---|---|---|
| REVOLUTION MEDICINES INC | 5.38% | |
| COGENT BIOSCIENCES INC | 4.91% | |
| MERCK & CO INC | 4.59% | |
| ELI LILLY & CO | 4.39% | |
| NOVARTIS AG | 3.98% | |
| BRISTOL-MYERS SQUIBB CO | 3.55% | |
| ABBVIE INC | 3.34% | |
| BEONE MEDICINES LTD | 3.15% | |
| JOHNSON & JOHNSON | 3.13% | |
| IMMUNOME INC | 2.94% |
Sector allocation
| Healthcare | 100.00% |
Geographic allocation
| United States | 80.71% |
| Switzerland | 10.05% |
| Denmark | 2.87% |
| United Kingdom | 3.04% |
| China | 1.92% |
| Germany | 0.80% |
| Other | 0.62% |
PortView Portfolio Insights
PortView analyzes how CANC fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze CANC in PortView →Related securities
Related stocks
Frequently asked questions
- What does CANC track?
- CANC is the Tema Oncology ETF, a Other ETF.
- What is the expense ratio of CANC?
- Expense ratio data for CANC is shown on the page when available from our data provider.
- What are the largest holdings in CANC?
- Top holdings include RVMD, COGT, MRK, LLY, NOVN.SW.
- How can PortView analyze CANC overlap with other ETFs?
- PortView computes the holdings overlap between CANC and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.